Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.31 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7116990 | 0.87 | L3MBTL1 (0.37) | MMP2MMP13SIGMAR1 | |
| SCHEMBL7116976 | 0.82 | MMP2 (0.30) | MMP2MMP13 | |
| SCHEMBL7122604 | 0.78 | SMN1; SMN2 (0.34) | MMP13 | |
| SCHEMBL7545570 | 0.77 | SIGMAR1 (0.35) | MMP2MMP13CTNNB1WNT3ACA12 | |
| SCHEMBL7117234 | 0.77 | CTNNB1 (0.36) | MMP13CTNNB1WNT3ACA12CA2 | |
| SCHEMBL7156507 | 0.76 | MMP13 (0.45) | MMP2MMP13CTNNB1WNT3AMEN1 | |
| SCHEMBL7156500 | 0.76 | MMP13 (0.45) | MMP2MMP13CTNNB1WNT3AMEN1 | |
| SCHEMBL7156503 | 0.76 | MMP13 (0.45) | MMP2MMP13CTNNB1WNT3AMEN1 | |
| SCHEMBL7127966 | 0.75 | ATM (0.35) | MMP13CTNNB1WNT3ACA12CA2 | |
| SCHEMBL7121623 | 0.74 | NPSR1 (0.32) | MMP2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | disclosed |
| EP-1265855-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001062715-A1 | NOVEL CD23 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | MMP2 1392/4885MMP13 335/4885CTNNB1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.